Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vistusertib - AstraZeneca

Drug Profile

Vistusertib - AstraZeneca

Alternative Names: AZD 2014

Latest Information Update: 17 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Massachusetts General Hospital; National Cancer Institute (USA); Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Queen Mary University of London; Samsung Medical Center; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Dec 2019 AstraZenca completes the phase-II OCTOPUS trial in Ovarian cancer (Second-line therapy or greater, Combination therapy) in United Kingdom (PO) (EudracT2014-005221-12) (ISRCTN16426935)
  • 29 Nov 2018 Discontinued - Phase-I for Prostate cancer (Early-stage disease, Neoadjuvant therapy) in United Kingdom (PO)
  • 29 Nov 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top